Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT01383148 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT01383148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01383148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Transgene
Phase
Phase 2/3
Overall status
Terminated
Start date
April 30, 2012
Completion date
July 31, 2016
Enrollment
222 (actual)
Sites
72

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung carcinoma